Company: AEMD
Filing Date: 2025-06-26
Form Type: 10-K
Source: 0001683168-25-004780
Chunk: 76

Company: AETHLON MEDICAL INC
Filing Date: 2025-06-26
Form: 10-K
Item: Item 1
Chunk 76
---
 issuance 319,518
shares of common stock for outstanding restricted stock units, stock options and warrants, excluding an aggregate of 71,432 issuances
of restricted stock units to our independent directors under our 2020 Equity Incentive Plan made subsequent to March 31, 2025. As of March
31, 2025, we had issued and outstanding 2,585,239 shares of common stock. As a result, as of March 31, 2025 we had 57,023,811 shares of
common stock available for issuance to new investors or for use to satisfy indebtedness or pay service providers.

 44 

On
March 16, 2025, Aethlon Medical, Inc. (the “Company”) entered into
an inducement offer to exercise existing Class A and Class B Warrants (the “Agreement”) with a certain accredited and institutional
holder (the “Holder”) of the Company’s outstanding Class A and Class B Warrants issued on May 17, 2024 (the “Existing
Warrants”). Pursuant to the Agreement, the Holder, upon exercise, will receive a new unregistered Common Stock Purchase Warrant
(“New Warrant”) pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended (“Securities Act”), to purchase
up to a number of shares equal to 200% of the number of Warrant Shares issued pursuant to the exercise of Existing Warrants pursuant to
this Agreement (the “New Warrant Shares”), which New Warrant shall have an exercise price per share equal to $0.3736, subject
to adjustment as provided in the New Warrant, will be exercisable at any time on or after six (6) months from the date of issuance and
have a term of exercise of five and one-half (5.5) years from the date of issuance and a reduction of the exercise price of the Existing
Warrants to $0.3736 per share, representing the closing price on March 14, 2025, but only with respect to a cash exercise under the
Existing Warrants (as reduced from the current respective exercise price per share as set forth in the Existing Warrants).

The
closing took place on March 17, 2025. Gross proceeds to the Company from the exercise of the Existing Warrants was $2,316,320, prior to
deducting closing costs and placement